(+)-JQ1

Catalog No.S7110

(+)-JQ1 Chemical Structure

Molecular Weight(MW): 456.99

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.

Size Price Stock Quantity  
USD 270 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

8 Customer Reviews

  • The BET protein inhibitor JQ1 reduces c-Myc expression and attenuates primary MCC cell proliferation. A, decreased c-Myc expression in MCC-3 and MCC-5 treated with JQ1 (800 nmol/L) for 72 hours by qRT-PCR and immunoblotting. The mRNA expression of target genes was normalized to that of MRPS2 and a value of 1.0 was assigned to the mRNA expression of target genes in the control group (means+SEM; **, P < 0.01 vs. control); b-actin was used as a loading control for immunoblotting.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

    Immunohistochemical staining of xenograft tumor tissues. Immunohistochemical staining of xenograft tumor tissues with the indicated antibodies. p21-, p27-, p57-, and Ki67 positive cells (brown staining) were quantified at x400 magnification (meansSEM;**, P < 0.01;***, P < 0.001 vs. control); scale bars, 10 um.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

  • (D) Effect of JQ1 on alterations of actin cytoskeleton in VEGF-induced HUVECs. The cells were pretreated with DMSO or JQ1 (100 nM) for 6 h, and stimulated with VEGF (10 ng/mL) for 12 h. F-actin (red) and nuclei (blue) were stained with phalloidin and DAPI, respectively. Representative images from 3 independent experiments.

    Sci Rep, 2016, 6:23770.. (+)-JQ1 purchased from Selleck.

    Sensitivity of BEZ235-resistant cells to JQ-1 using the MTT assay.

    Oncotarget, 2016, 6(7):5134-46.. (+)-JQ1 purchased from Selleck.

  • B. Repressed MCC-3 xenograft tumor growth upon combined treatment with MLN0128 and JQ1. Tumor bearing mice were treated with MLN0128 or vehicle at 1 mg/kg/day by oral gavage and JQ1 or vehicle at 50 mg/kg/day by i.p. injection for a period of 30 days. C. A more effective reduction of MCC-3 xenograft tumor growth in the group treated with combined therapy. Fold-reduction of tumor growth was calculated as average tumor growth of control group divided by average tumor growth of treatment group. Tumor growth was calculated as final average tumor volume minus initial average tumor volume in each group.

    Oncotarget, 2016, 7(6):6576-92.. (+)-JQ1 purchased from Selleck.

    JQ1 induces cell cycle arrest and apoptosis in Cal27 cells. (C) Cal27 cells were treated with JQ1 for 24 h and whole cell lysates were tested by western blot assays for the expression of cleaved-caspase-3. GAPDH was used as a loading control. (D) Apoptosis of Cal27 cells treated with JQ1 at 0 and 0.5 µM JQ1; *P<0.05 vs. control (the DMSO group)

    Oncol Rep, 2016, 36(4):1989-96.. (+)-JQ1 purchased from Selleck.

  • immunofluorescence staining of BRD4 in ACC-LM and ACC-83 cells treated with JQ1 at the concentration of 1 µM for 24 h (×200).

    Biol Res, 2017, 50(1):19. (+)-JQ1 purchased from Selleck.

    Effect of BET domain family inhibition on AMI damage in cardiomyocytes. (A) LDH and (B) CK-MB activity in the serum. #P<0.01 vs. sham group; @P<0.05 and &P<0.01 vs. AMI group. BET, bromodomain and extra-terminal; AMI, acute myocardial infarction; LDH, lactate dehydrogenase; CK-MB, creatine kinase MB isoenzyme.

    Exp Ther Med, 2015, 10(6):2319-2324.. (+)-JQ1 purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description (+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.
Features (+)-JQ1 is more effective than (-)-JQ1.
Targets
BRD4 (2) [1]
(Cell-free assay)
BRD4 (1) [1]
(Cell-free assay)
33 nM 77 nM
In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. [1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. [2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. [3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K1  MWXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mmr2NlUxNzVyMD:xNFAxKG6P NWTYVZRmOjRxNEivO|IhcA>? M1LwbmROW09? Ml7DbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> M3PTclI3PzB5OEix
BCPAP M1LO[GNmdGxiVnnhZoltcXS7IFHzd4F6 NHPXOIwzPTBxNUCwM|ExODBibl2= NUXHR3dDOjRxNEivO|IhcA>? NV7XeFJCTE2VTx?= NUjReZI4cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmNSCjbnSgeIlu\S1iZHXw[Y5l\W62IH3hco5meg>? M2TB[VI3PzB5OEix
K1  M4jrd2NmdGxiQ4njcIUhSXO|YYm= MVKyOVAwPTByL{GwNFAhdk1? M4XRbFczKGh? NX;Bepp2TE2VTx?= M32zWYFzemW|dIOgZ4VtdCCleXPs[UBifCCJMD;HNUBxcGG|ZR?= MYGyOlcxPzh6MR?=
BCPAP MnLqR4VtdCCFeXPs[UBCe3OjeR?= NUDhSotNOjVyL{WwNE8yODByIH7N M{\5OFczKGh? MYfEUXNQ NH7rT4tienKnc4TzJINmdGxiY4njcIUh[XRiR{CvS|EheGijc3W= NH;5OGEzPjdyN{i4NS=>
Hep3B MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjNTlFNOC1zMDFOwG0> NH3hWWs2KGR? MkTHSG1UVw>? NWDJcGlSUUN3ME2wMlA5KM7:TR?= MXOyOlU4PTF4Nx?=
HCCLM3 NIfFXohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvDNE0yOCEQvF2= M4PvWlUh\A>? M4\WSWROW09? MUnJR|UxRTBwMUSg{txO MkK0NlY2PzVzNke=
HuH7 M4\LSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXmwMVExKM7:TR?= M3PVNlUh\A>? NFexZW5FVVOR NEnMR2hKSzVyPUCuNlEh|ryP NHfqTngzPjV5NUG2Oy=>
HepG2 NHjMeGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHJbGExNTFyIN88US=> MX21JIQ> M3rMUWROW09? NGe5cYtKSzVyPUCuN|Qh|ryP MmDPNlY2PzVzNke=
SMMC7721 NF7STVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPhUo8xNTFyIN88US=> Mnr2OUBl MmPWSG1UVw>? NGWyS29KSzVyPUCuOFEh|ryP M1juN|I3PTd3MU[3
BEL7402 MlrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn73NE0yOCEQvF2= Mme2OUBl NUjH[GVJTE2VTx?= Mn;RTWM2OD1yLkS3JO69VQ>? MljBNlY2PzVzNke=
MHCC97H NXXJUGZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDuenlnOC1zMDFOwG0> MnXFOUBl M3LhZmROW09? MoXHTWM2OD1yLkSxJO69VQ>? NFz0PHczPjV5NUG2Oy=>
Hep3B NUW1V5NOS2WubDDDfYNt\SCDc4PhfS=> Mo\RNE4yNzBwNT:yMlUh|ryP Mo\5OFghcA>? Mlf3SG1UVw>? MYHs[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kBJS0NiY3XscJMhcW5ic4XiMWcyKHCqYYPlxsA> M2W1O|I3PTd3MU[3
HCCLM3 M331R2NmdGxiQ4njcIUhSXO|YYm= MWKwMlEwOC53L{KuOUDPxE1? M{PPRVQ5KGh? M1fNdWROW09? M1:3eoxm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKEiFQzDj[YxteyCrbjDzeYIuTzFicHjhd4XDqA>? NF2wfHUzPjV5NUG2Oy=>
Hep3B MUXBdI9xfG:|aYOgRZN{[Xl? M4TRXlAvOS9yLkWvNk42KM7:TR?= NGjmWJo1QCCq NFXoRZdFVVOR MXHhZ5RqfmG2ZYOgZ4F{eGG|ZT2zJIFv\CClYYPwZZNmNTliZYjwdoV{e2mxbjDhcoQhcW6mdXPl[EBRSVKSIHPs[YF3[WenIHHzJJdmdGxiYYOgZ5l1d2Oqcn;t[UBkKHKnbHXhd4UhcW62bzD0bIUh[3m2b4DsZZNuKG[{b32gcYl1d2Oqb37kdoli NX;1enFKOjZ3N{WxOlc>
HCCLM3 NY\PN|V4SXCxcITvd4l{KEG|c3H5 NUTKRmVHOC5zL{CuOU8zNjVizszN MnPZOFghcA>? NHPkUmxFVVOR MoGzZYN1cX[jdHXzJINie3Cjc3WtN{BidmRiY3HzdIF{\S17IHX4dJJme3Orb36gZY5lKGmwZIXj[YQhWEGUUDDjcIVifmGpZTDhd{B4\WyuIHHzJIN6fG:laILvcYUh[yC{ZXzlZZNmKGmwdH:geIhmKGO7dH;wcIF{dSCocn;tJI1qfG:laH;u[JJq[Q>? MkXlNlY2PzVzNke=
A549 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrTNE4yNTFyIN88US=> MlrDO|IhcA>? MYPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M{Hr[FI3PDF3MkK1
H157 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUSwMlEuOTBizszN NXTJWo5jPzJiaB?= MWPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M{jOXlI3PDF3MkK1
H1299 NVvzeHFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvvNE4yNTFyIN88US=> M2TKflczKGh? NWq0enpIcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NXG4W3hFOjZ2MUWyNlU>
A549 MkfzSpVv[3Srb36gRZN{[Xl? NHz6TlcyNzJwNT:1JO69VQ>? MnzWNVIhcA>? NU\3WXdCyqC5ZXHrcJkh\GWlcnXhd4VlKEKlbD2yJIxmfmWucx?= M1Hud|I3PDF3MkK1
H1299 MnfKSpVv[3Srb36gRZN{[Xl? MmXrNU8zNjVxNTFOwG0> Mn\jNVIhcA>? M1TscOKhf2Wja3z5JIRm[3KnYYPl[EBD[2xvMjDs[ZZmdHN? MYGyOlQyPTJ{NR?=
H157 NX3JVFF1TnWwY4Tpc44hSXO|YYm= M2ftW|EwOi53L{Wg{txO MXWxNkBp NFj6V|Jl\WO{ZXHz[YQhTFJ2IHX4dJJme3Orb36= NUfVenRWOjZ2MUWyNlU>
H1299 NWXXVZJkTnWwY4Tpc44hSXO|YYm= NILaWW4yNzJwNT:1JO69VQ>? MkfiNVIhcA>? NIrqZm1l\WO{ZXHz[YQhTFJ2IHX4dJJme3Orb36= Mmr0NlY1OTV{MkW=
C8161 Mk\OR4VtdCCYaXHibYxqfHliQYPzZZk> MWWwMVIh|ryP NW\0OpZ[PCCm MYLEUXNQ MXzk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NXXEOWVYOjZ|OUeyNlM>
Mel285 MXrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NWTtdVduOC1{IN88US=> MWC0JIQ> Mn3tSG1UVw>? Mlvh[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M1XJS|I3Ozl5MkKz
Mel290 M3rrPWNmdGxiVnnhZoltcXS7IFHzd4F6 NUTtbGR2OC1{IN88US=> M{myc|Qh\A>? MWfEUXNQ NF3Ubphl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NWrQZ3Q3OjZ|OUeyNlM>
92.1 NUDRdHVvS2WubDDWbYFjcWyrdImgRZN{[Xl? NYTOVZlqOC1{IN88US=> MX:0JIQ> NHXqXmZFVVOR MWDk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MWOyOlM6PzJ{Mx?=
Omm1.3 NVjmfWJuS2WubDDWbYFjcWyrdImgRZN{[Xl? NWDleZN2OC1{IN88US=> MVO0JIQ> MnHSSG1UVw>? NH:0Vndl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MUGyOlM6PzJ{Mx?=
Mel202 NInFVoxE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVXxZnpuOC1{IN88US=> M4fUUVQh\A>? NXnHPJlUTE2VTx?= NU\kNGdm\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MmO4NlY{QTd{MkO=
Mel270 NEDIeFhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4fP[|AuOiEQvF2= M1XIUlQh\A>? MlTXSG1UVw>? MonT[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NHO5OZUzPjN7N{KyNy=>
Omm1 MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MVWwMVIh|ryP MkDuOEBl M{nVfGROW09? M1jTb4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M{n2ZlI3Ozl5MkKz
92.1 MYnBdI9xfG:|aYOgRZN{[Xl? MXm1NFAhdk1? M{jDPVQ5KGh? NFXhRYdFVVOR NXn5fllPcW6mdXPld{BieG:ydH;zbZM> Mn\pNlY{QTd{MkO=
Omm1.3 M3XyV2Fxd3C2b4Ppd{BCe3OjeR?= MknROVAxKG6P M4r1V|Q5KGh? NI\MNlRFVVOR NVT0ZYFpcW6mdXPld{BieG:ydH;zbZM> M{jhZ|I3Ozl5MkKz
92.1 NGfiNZlE\WyuIFP5Z4xmKEG|c3H5 MYm1NFAhdk1? NGniNY4zPC92OD:3NkBp M2fx[WROW09? MWjpcoR2[2W|IITo[UBk\WyuIHHjZ5VufWyjdHnvckBifCC|dXKtS|HDqA>? NFzydFIzPjN7N{KyNy=>
Omm1.3 MVnD[YxtKEO7Y3zlJGF{e2G7 NH7mR2c2ODBibl2= MmPkNlQwPDhxN{KgbC=> MV\EUXNQ MV3pcoR2[2W|IITo[UBk\WyuIHHjZ5VufWyjdHnvckBifCC|dXKtS|HDqA>? MkTzNlY{QTd{MkO=
A549 NGS5ZWVHfW6ldHnvckBCe3OjeR?= NXm1bXRXOTByL{SwNE8yODByIH7N NUnt[pNoOjRiaB?= M3zmbZVxemWpdXzheIV{KGGwZDDhZ5RqfmG2ZYOgV2lTXDF? NY\VeJZWOjZ{MUKxPVk>
MCF-7 M3PKSWZ2dmO2aX;uJGF{e2G7 MnXzNVAxNzRyMD:xNFAxKG6P NYXUcW5JOjRiaB?= M3TQPZVxemWpdXzheIV{KGGwZDDhZ5RqfmG2ZYOgV2lTXDF? M1HYdVI3OjF{MUm5
HEK293 MoDuSpVv[3Srb36gRZN{[Xl? NYfLcFc5OTByL{SwNE8yODByIH7N NYPN[GZrOjRiaB?= MnfNeZBz\We3bHH0[ZMh[W6mIHHjeIl3[XSnczDTTXJVOQ>? M4nBcFI3OjF{MUm5
858 M2D1OWNmdGxiVnnhZoltcXS7IFHzd4F6 NInvR|cxNTFizszN NIrHRZM2KGR? NUDSSnRHTE2VTx?= MYXk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NHThZXkzPjJyNkOzNy=>
DDR2L63V M1Wwc2NmdGxiVnnhZoltcXS7IFHzd4F6 MmS1NE0yKM7:TR?= NVuwdVFtPSCm MVPEUXNQ Mn7D[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MnHsNlYzODZ|M{O=
BE(2)-C NXPqTlNUS2WubDDWbYFjcWyrdImgRZN{[Xl? NGjX[XcyKM7:TR?= NEfqcHUyNTRiZB?= Mn\W[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> MkTTNlYxPjd2NkS=
IMR-32 NXjKboU4S2WubDDWbYFjcWyrdImgRZN{[Xl? NYnRWJE5OSEQvF2= M2XMXlEuPCCm NIq1[ppl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? NITLVHUzPjB4N{S2OC=>
JF NETsbFFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M{LrUVEh|ryP NIm5UZMyNTRiZB?= MmPJ[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> MVmyOlA3PzR4NB?=
BE(2)-M17 NWrvenR5S2WubDDWbYFjcWyrdImgRZN{[Xl? NUXEOGdoOSEQvF2= M{fvZ|EuPCCm NHPE[nll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? Mnu1NlYxPjd2NkS=
SK-N-SH MkPUR4VtdCCYaXHibYxqfHliQYPzZZk> MoHsNUDPxE1? Mn7ONU01KGR? NWK0eot5\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? Mn71NlYxPjd2NkS=
SK-N-DZ  MUfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NEDRV4QyKM7:TR?= MkP2NU01KGR? NILtdZVl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? MUWyOlA3PzR4NB?=
HMC-1.1  NWmxb5dzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXq1MVUxODBibl2= MXe0PEBp MkDrSG1UVw>? NEnUOnJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MV2yOlA2PTNyMx?=
HMC-1.2 NUXsXpdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDIZWE2NTVyMECgcm0> NUn4WVlsPDhiaB?= NGPJUm1FVVOR NXfLfVdScW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M4S2[FI3ODV3M{Cz
ROSA KIT WT  MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\hVJU2NTVyMECgcm0> MnTwOFghcA>? M2\WXmROW09? NHTFcXpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NUPjTHU6OjZyNUWzNFM>
ROSA KIT D816V NULndlZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\MOU02ODByIH7N M4XEcFQ5KGh? NWHx[WJVTE2VTx?= Mkj0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MmjKNlYxPTV|MEO=
HMC-1.1  MonuRZBweHSxc3nzJGF{e2G7 NYHRUnpROjByLUWwNFAhdk1? MnzxOFghcA>? NE\nXHpFVVOR NGHZXnZqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NXjCdFZtOjZyNUWzNFM>
HMC-1.2 NXXNfIRVSXCxcITvd4l{KEG|c3H5 NHPoVlYzODBvNUCwNEBvVQ>? Mmr6OFghcA>? MkHnSG1UVw>? NWnRWm1YcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NX:4SopOOjZyNUWzNFM>
ROSA KIT WT  NWj0VJF{SXCxcITvd4l{KEG|c3H5 NUezNXZWOjByLUWwNFAhdk1? MkTSOFghcA>? NWD4cI8xTE2VTx?= MmPTbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlWzNlYxPTV|MEO=
ROSA KIT D816V MnXqRZBweHSxc3nzJGF{e2G7 MlT6NlAxNTVyMECgcm0> MVS0PEBp M2DZ[GROW09? M2DmWolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3LjVFI3ODV3M{Cz
494H NFfxOpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\TPFczKGh? MULEUXNQ M1\qVGlEPTB;MD6xNlLDuTBwMEC0JO69VQ>? MnnoNlU6PDR3Nk[=
493H M{XsdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXO3NkBp NWDsPXBbTE2VTx?= NWqyXZFuUUN3ME2wMlA1P8LzMD6wNFkh|ryP NWP3WHFKOjV7NES1OlY>
716H MnrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XReVczKGh? NWjrR5FETE2VTx?= MmTSTWM2OD1yLkKxNuKyOC5yM{Sg{txO M37ucVI2QTR2NU[2
148I NVPyN45wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4C3R|czKGh? MnfHSG1UVw>? NHLrW3NKSzVyPUCuNlg1yrFyLkCzOUDPxE1? NUG2NZpDOjV7NES1OlY>
98Sc M3nlO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3QR244OiCq NXrGTXJqTE2VTx?= NIDHbmtKSzVyPUCuNVE2yrFyLkCwOEDPxE1? NGTsSmczPTl2NEW2Oi=>
89R MmD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULYWWk1PzJiaB?= NV;YS5dWTE2VTx?= MlnvTWM2OD1yLkGyOuKyOC5yMEOg{txO MmnRNlU6PDR3Nk[=
494L M3nIZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3P0flczKGh? NGTubnhFVVOR MVzJR|UxRTBwM{G3xtExNjBzMjFOwG0> NHXJelUzPTl2NEW2Oi=>
493L NH3EVXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfFSFI4OiCq M3W3ZWROW09? M2HqdWlEPTB;MD6wOVDDuTBwMEGxJO69VQ>? MmrDNlU6PDR3Nk[=
148L MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nhTVczKGh? MlfrSG1UVw>? NVWwR5hiUUN3ME2wMlE1PsLzMD6wNVch|ryP NEH5NVAzPTl2NEW2Oi=>
98L NF7HPJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETKS2o4OiCq M12wNmROW09? MnS1TWM2OD1yLkOwPeKyOC5yMkmg{txO MWiyOVk1PDV4Nh?=
OS17 MmDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXzO|IhcA>? NWW4PWFDTE2VTx?= M4\wTmlEPTB;MD6wO|nDuTBwMECzJO69VQ>? Mm\qNlU6PDR3Nk[=
OS9 MorJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPJO|IhcA>? M2XySmROW09? NG[3NYpKSzVyPUCuOFA3yrFyLkCyPEDPxE1? NIHVeIQzPTl2NEW2Oi=>
MG63 NYS2S3FnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTNO|IhcA>? NW\1OI5jTE2VTx?= MXrJR|UxRTBwMUG0xtExNjB{NTFOwG0> NVfuc5U3OjV7NES1OlY>
SAOS2 MnvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3o[|M4OiCq MlfFSG1UVw>? M1HWO2lEPTB;MD6yNVfDuTBwMECzJO69VQ>? MVGyOVk1PDV4Nh?=
U2OS NXXCZYlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Lj[VczKGh? MkXqSG1UVw>? Ml;ITWM2OD1yLkG5POKyOC5yMEig{txO Mn\pNlU6PDR3Nk[=
SJSA-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFi4bYw4OiCq M1LsfmROW09? MYfJR|UxRTBwMUCwxtExNjBzMDFOwG0> NWG2[ZBZOjV7NES1OlY>
494H MVnBdI9xfG:|aYOgRZN{[Xl? M37yO|AvOjVxMD61M|EvOCEQvF2= MlPuNlQhcA>? MnLSSG1UVw>? MoDxbY5kemWjc3XzJIxmfmWuczDv[kBkdGWjdnXkJINie3Cjc3WtN:Kh Mk\CNlU6PDR3Nk[=
148I NXzYcFVISXCxcITvd4l{KEG|c3H5 NVviNJg5OC5{NT:wMlUwOS5yIN88US=> MmDqNlQhcA>? MUDEUXNQ NITQN2JqdmO{ZXHz[ZMhdGW4ZXzzJI9nKGOuZXH2[YQh[2G|cHHz[U0{yqB? M4O1XlI2QTR2NU[2
OS17 NGfU[opCeG:ydH;zbZMhSXO|YYm= NHjjOmMxNjJ3L{CuOU8yNjBizszN NWnOTppTOjRiaB?= MofkSG1UVw>? MX;pcoNz\WG|ZYOgcIV3\Wy|IH;mJINt\WG4ZXSgZ4F{eGG|ZT2zxsA> MlG1NlU6PDR3Nk[=
494H NY\rT483SXCxcITvd4l{KEG|c3H5 NUSzXFM3OeLCid88US=> M3L3UFQ5KGh? MXXEUXNQ Mlq0bY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5 MmTwNlU6PDR3Nk[=
148I M4LN[2Fxd3C2b4Ppd{BCe3OjeR?= M4nuclHjiIoQvF2= MkTzOFghcA>? MoXLSG1UVw>? NVLX[ohJcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 M3jlPFI2QTR2NU[2
OS17 MXjBdI9xfG:|aYOgRZN{[Xl? M3XiW|HjiIoQvF2= M3rneFQ5KGh? MmTTSG1UVw>? M1[1bYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfS=> M3vLd|I2QTR2NU[2
MOLM13 MYfBdI9xfG:|aYOgRZN{[Xl? M3jRelI2OCCwTR?= NGLDVHg1QCCq MXvEUXNQ MVjpcoR2[2W|IIPp[45q\mmlYX70cJkh[XCxcITvd4l{KGOxdILlZZRu\W62IIfpeIgheXWrenHyeIlvcWJ? MnTWNlUxPTN6MkW=
MV4-11  Mk\GRZBweHSxc3nzJGF{e2G7 NEP0OpYzPTBibl2= MVO0PEBp NEP5WWJFVVOR NWHwTnMxcW6mdXPld{B{cWewaX\pZ4FvfGy7IHHwc5B1d3OrczDjc5Rz\WG2bXXueEB4cXSqIIH1bZpienSrbnni M3fJOlI2ODV|OEK1
MOLM13 MVLGeY5kfGmxbjDBd5NigQ>? NWDo[YQ{OjVyIH7N MoDJNlQhcA>? NXXnOI9yTE2VTx?= NGfHN2pmdmijbnPld{ByfWm8YYL0bY5q[i2rbnT1Z4VlKG2xcnWgdFIyNCCESV2sJIFv\CClbHXheoVlKFCDUmC= M1nBcVI2ODV|OEK1
MV4-11  MoPQSpVv[3Srb36gRZN{[Xl? NVfSO25GOjVyIH7N MYmyOEBp MWrEUXNQ NX;XNZV[\W6qYX7j[ZMheXWrenHyeIlvcWJvaX7keYNm\CCvb4LlJJAzOSxiQlnNMEBidmRiY3zlZZZm\CCSQWLQ NYLNbnJ1OjVyNUO4NlU>
MOLM13 NGS4VWRCeG:ydH;zbZMhSXO|YYm= MlfHNlUxKG6P MkOxOFghcA>? M1LkRmROW09? NGTDflZqdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicH;uZZRqdmmk NWrPNnp7OjVyNUO4NlU>
MV4-11  NVjRcGF1SXCxcITvd4l{KEG|c3H5 MUiyOVAhdk1? MXi0PEBp M2foO2ROW09? NGL6XlhqdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicH;uZZRqdmmk NEj0[3AzPTB3M{iyOS=>
Hela M1\hbmNmdGxiVnnhZoltcXS7IFHzd4F6 NFnEPVkxNTVyMDDuUS=> M37oRlczKGh? NHfV[ZBFVVOR M1HkNoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NGHrdoQzPTByOUK5OS=>
HBL-1 NF;vNYFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MmLRNE02ODBibl2= NXvr[Xc3PzJiaB?= NGHzfoFFVVOR NW\Ee2xK\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M2LmcFI2ODB7Mkm1
HLY-1 NIL0e21E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NUjGVJBCOC13MECgcm0> NYXFPXh2PzJiaB?= M4K4R2ROW09? NIXufo5l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M{nJeVI2ODB7Mkm1
OCI-Ly3 MXHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NF;4PJQxNTVyMDDuUS=> Mkj0O|IhcA>? MmW4SG1UVw>? MUjk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MmS1NlUxODl{OUW=
OCI-Ly10 M3fiVWNmdGxiVnnhZoltcXS7IFHzd4F6 MYiwMVUxOCCwTR?= MnPZO|IhcA>? M{PhPWROW09? NU\CVIhS\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M3u1d|I2ODB7Mkm1
SU-DHL-4 NHywTnpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NUPoPHpbOC13MECgcm0> MXu3NkBp NWLQTm85TE2VTx?= M2LJ[4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M4jZWFI2ODB7Mkm1
SU-DHL-5 MoTnR4VtdCCYaXHibYxqfHliQYPzZZk> NH;YPXExNTVyMDDuUS=> NWnQfZhkPzJiaB?= MUHEUXNQ NIrWNGRl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NHyxRVkzPTByOUK5OS=>
SU-DHL-6 M1TMU2NmdGxiVnnhZoltcXS7IFHzd4F6 MVGwMVUxOCCwTR?= NHiyfog4OiCq Mkm0SG1UVw>? M4TVXYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M3L2eVI2ODB7Mkm1
SU-DHL-10 M1LUemNmdGxiVnnhZoltcXS7IFHzd4F6 M33MbFAuPTByIH7N MnjWO|IhcA>? NYq3e2Q5TE2VTx?= Mk\4[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NI\tPW0zPTByOUK5OS=>
RC-K8 M{G1SmNmdGxiVnnhZoltcXS7IFHzd4F6 MVywMVUxOCCwTR?= M3TPTFczKGh? MYjEUXNQ M4K0RoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MmLoNlUxODl{OUW=
OCI-Ly8 NEfrU2tE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVSxc3FqOC13MECgcm0> MWe3NkBp NEnzZpZFVVOR MXnk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MUSyOVAxQTJ7NR?=
OCL-Ly18 MlX6R4VtdCCYaXHibYxqfHliQYPzZZk> NWrw[5NnOC13MECgcm0> MVy3NkBp NFPReVVFVVOR NYj2XZZy\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NGfvTZczPTByOUK5OS=>
OCI-Ly3 NHTGTWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLqXHQyPzJxMkWwM|UxOCCwTR?= NFrPTVQzNzdiZB?= NFXPb5FFVVOR NIr3XG5qdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg NUTYVoFMOjVyMEmyPVU>
OCI-Ly8 NGX4eZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mon5NVczNzJ3MD:1NFAhdk1? M2CxNFIwPyCm MYfEUXNQ NWD0NWdscW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeEBifCC|dXKtS|Ehf2m2aDDtbY5qdWGuIHPlcIwh\GWjdHlCpC=> M4\Jd|I2ODB7Mkm1
SU-DHL-4 NGnGc3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXixO|IwOjVyL{WwNEBvVQ>? NF3sPGUzNzdiZB?= M4GwPWROW09? NVq3ZmhocW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeEBifCC|dXKtS|Ehf2m2aDDtbY5qdWGuIHPlcIwh\GWjdHlCpC=> MYeyOVAxQTJ7NR?=
SU-DHL-10 NEiyNpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzaUnEyPzJxMkWwM|UxOCCwTR?= Mof3Nk84KGR? M4jtPGROW09? MVzpcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2IHH0JJN2[i2JMTD3bZRpKG2rbnntZYwh[2WubDDk[YF1cMLi NF;5SmMzPTByOUK5OS=>
OCI-Ly3 MnHSRZBweHSxc3nzJGF{e2G7 MU[xO|IwOjVyIH7N MlnMO4Q> M3[yZ2ROW09? M1zxc4lv[3KnYYPld{Bk[XOyYYPlMVMwPyCjY4Tpeol1gcLic3nncolncWOjboTsfS=> Mn20NlUxODl{OUW=
OCI-Ly8 M2X1cmFxd3C2b4Ppd{BCe3OjeR?= MUOxO|IwOjVyIH7N NVK2V3ZVP2R? NXHsPY9rTE2VTx?= M1Xj[Ylv[3KnYYPld{Bk[XOyYYPlMVMwPyCjY4Tpeol1gcLic3nncolncWOjboTsfS=> MYSyOVAxQTJ7NR?=
SU-DHL-4 NEXNV5pCeG:ydH;zbZMhSXO|YYm= M3rqV|E4Oi9{NUCgcm0> M33lT|dl NVPXUIpETE2VTx?= MnnsbY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 MoXGNlUxODl{OUW=
SU-DHL-10 MUHBdI9xfG:|aYOgRZN{[Xl? Mnu2NVczNzJ3MDDuUS=> MXK3[C=> Mn;nSG1UVw>? MmHHbY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 MorlNlUxODl{OUW=

... Click to View More Cell Line Experimental Data

In vivo (+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. [1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. [2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: MC 11060 cells
  • Concentrations: ~500 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Mice bearing NMC 797 xenografts
  • Formulation: 5% DMSO in 5% dextrose
  • Dosages: 50 mg/kg
  • Administration: intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL warmed (199.12 mM)
Ethanol 91 mg/mL (199.12 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 456.99
Formula

C23H25ClN4O2S

CAS No. 1268524-70-4
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can I reconstitute the compound for in vivo injection?

  • Answer:

    JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy (+)-JQ1 | (+)-JQ1 supplier | purchase (+)-JQ1 | (+)-JQ1 cost | (+)-JQ1 manufacturer | order (+)-JQ1 | (+)-JQ1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID